John V. W. Reynders
Direktor/Vorstandsmitglied bei Rare-X
Aktive Beziehungen
Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
---|---|---|---|---|
Nicole Boice | F | - |
Rare-X
Rare-X Packaged SoftwareTechnology Services Part of Global Genes, Rare-X is a patient advocacy organization based in Washington. Rare-X is focused on supporting the acceleration and development of life-altering treatments and future cures for patients impacted by a rare disease. Rare-X is building the largest collaborative patient-driven, open-data access project for rare diseases ly, gathering structured, fit-for-purpose data to share broadly, benefitting from 21st-century governance, consent, and federated data sharing technology. Rare-X's goal is to build the largest collaborative patient-driven, open-data access project for rare diseases ly. The American company was founded in 2019 by Nicole Boice. The CEO is Charlene Son Rigby. Rare-X was acquired by Global Genes on February 07, 2023. | 5 Jahre |
Gianluca Pirozzi | M | 47 | 5 Jahre | |
Bethany Kraynack | F | - |
Rare-X
Rare-X Packaged SoftwareTechnology Services Part of Global Genes, Rare-X is a patient advocacy organization based in Washington. Rare-X is focused on supporting the acceleration and development of life-altering treatments and future cures for patients impacted by a rare disease. Rare-X is building the largest collaborative patient-driven, open-data access project for rare diseases ly, gathering structured, fit-for-purpose data to share broadly, benefitting from 21st-century governance, consent, and federated data sharing technology. Rare-X's goal is to build the largest collaborative patient-driven, open-data access project for rare diseases ly. The American company was founded in 2019 by Nicole Boice. The CEO is Charlene Son Rigby. Rare-X was acquired by Global Genes on February 07, 2023. | 4 Jahre |
Piyush Sharma | M | - | 7 Jahre | |
Angeli Moeller | M | - |
Rare-X
Rare-X Packaged SoftwareTechnology Services Part of Global Genes, Rare-X is a patient advocacy organization based in Washington. Rare-X is focused on supporting the acceleration and development of life-altering treatments and future cures for patients impacted by a rare disease. Rare-X is building the largest collaborative patient-driven, open-data access project for rare diseases ly, gathering structured, fit-for-purpose data to share broadly, benefitting from 21st-century governance, consent, and federated data sharing technology. Rare-X's goal is to build the largest collaborative patient-driven, open-data access project for rare diseases ly. The American company was founded in 2019 by Nicole Boice. The CEO is Charlene Son Rigby. Rare-X was acquired by Global Genes on February 07, 2023. | - |
Katherine Maynard | F | - |
Rare-X
Rare-X Packaged SoftwareTechnology Services Part of Global Genes, Rare-X is a patient advocacy organization based in Washington. Rare-X is focused on supporting the acceleration and development of life-altering treatments and future cures for patients impacted by a rare disease. Rare-X is building the largest collaborative patient-driven, open-data access project for rare diseases ly, gathering structured, fit-for-purpose data to share broadly, benefitting from 21st-century governance, consent, and federated data sharing technology. Rare-X's goal is to build the largest collaborative patient-driven, open-data access project for rare diseases ly. The American company was founded in 2019 by Nicole Boice. The CEO is Charlene Son Rigby. Rare-X was acquired by Global Genes on February 07, 2023. | - |
Craig Martin | M | - |
Rare-X
Rare-X Packaged SoftwareTechnology Services Part of Global Genes, Rare-X is a patient advocacy organization based in Washington. Rare-X is focused on supporting the acceleration and development of life-altering treatments and future cures for patients impacted by a rare disease. Rare-X is building the largest collaborative patient-driven, open-data access project for rare diseases ly, gathering structured, fit-for-purpose data to share broadly, benefitting from 21st-century governance, consent, and federated data sharing technology. Rare-X's goal is to build the largest collaborative patient-driven, open-data access project for rare diseases ly. The American company was founded in 2019 by Nicole Boice. The CEO is Charlene Son Rigby. Rare-X was acquired by Global Genes on February 07, 2023. | - |
Wendy Erler | F | - |
Rare-X
Rare-X Packaged SoftwareTechnology Services Part of Global Genes, Rare-X is a patient advocacy organization based in Washington. Rare-X is focused on supporting the acceleration and development of life-altering treatments and future cures for patients impacted by a rare disease. Rare-X is building the largest collaborative patient-driven, open-data access project for rare diseases ly, gathering structured, fit-for-purpose data to share broadly, benefitting from 21st-century governance, consent, and federated data sharing technology. Rare-X's goal is to build the largest collaborative patient-driven, open-data access project for rare diseases ly. The American company was founded in 2019 by Nicole Boice. The CEO is Charlene Son Rigby. Rare-X was acquired by Global Genes on February 07, 2023. | - |
Betsy Bogard | F | - |
Rare-X
Rare-X Packaged SoftwareTechnology Services Part of Global Genes, Rare-X is a patient advocacy organization based in Washington. Rare-X is focused on supporting the acceleration and development of life-altering treatments and future cures for patients impacted by a rare disease. Rare-X is building the largest collaborative patient-driven, open-data access project for rare diseases ly, gathering structured, fit-for-purpose data to share broadly, benefitting from 21st-century governance, consent, and federated data sharing technology. Rare-X's goal is to build the largest collaborative patient-driven, open-data access project for rare diseases ly. The American company was founded in 2019 by Nicole Boice. The CEO is Charlene Son Rigby. Rare-X was acquired by Global Genes on February 07, 2023. | - |
Tamar Thompson | F | 50 | 5 Jahre | |
Anthony Philippakis | M | 48 |
Rare-X
Rare-X Packaged SoftwareTechnology Services Part of Global Genes, Rare-X is a patient advocacy organization based in Washington. Rare-X is focused on supporting the acceleration and development of life-altering treatments and future cures for patients impacted by a rare disease. Rare-X is building the largest collaborative patient-driven, open-data access project for rare diseases ly, gathering structured, fit-for-purpose data to share broadly, benefitting from 21st-century governance, consent, and federated data sharing technology. Rare-X's goal is to build the largest collaborative patient-driven, open-data access project for rare diseases ly. The American company was founded in 2019 by Nicole Boice. The CEO is Charlene Son Rigby. Rare-X was acquired by Global Genes on February 07, 2023. | - |
Ilana Fogelman | F | - |
Rare-X
Rare-X Packaged SoftwareTechnology Services Part of Global Genes, Rare-X is a patient advocacy organization based in Washington. Rare-X is focused on supporting the acceleration and development of life-altering treatments and future cures for patients impacted by a rare disease. Rare-X is building the largest collaborative patient-driven, open-data access project for rare diseases ly, gathering structured, fit-for-purpose data to share broadly, benefitting from 21st-century governance, consent, and federated data sharing technology. Rare-X's goal is to build the largest collaborative patient-driven, open-data access project for rare diseases ly. The American company was founded in 2019 by Nicole Boice. The CEO is Charlene Son Rigby. Rare-X was acquired by Global Genes on February 07, 2023. | - |
Alvin Shih | M | 47 |
Rare-X
Rare-X Packaged SoftwareTechnology Services Part of Global Genes, Rare-X is a patient advocacy organization based in Washington. Rare-X is focused on supporting the acceleration and development of life-altering treatments and future cures for patients impacted by a rare disease. Rare-X is building the largest collaborative patient-driven, open-data access project for rare diseases ly, gathering structured, fit-for-purpose data to share broadly, benefitting from 21st-century governance, consent, and federated data sharing technology. Rare-X's goal is to build the largest collaborative patient-driven, open-data access project for rare diseases ly. The American company was founded in 2019 by Nicole Boice. The CEO is Charlene Son Rigby. Rare-X was acquired by Global Genes on February 07, 2023. | - |
Charlene Rigby | F | - |
Rare-X
Rare-X Packaged SoftwareTechnology Services Part of Global Genes, Rare-X is a patient advocacy organization based in Washington. Rare-X is focused on supporting the acceleration and development of life-altering treatments and future cures for patients impacted by a rare disease. Rare-X is building the largest collaborative patient-driven, open-data access project for rare diseases ly, gathering structured, fit-for-purpose data to share broadly, benefitting from 21st-century governance, consent, and federated data sharing technology. Rare-X's goal is to build the largest collaborative patient-driven, open-data access project for rare diseases ly. The American company was founded in 2019 by Nicole Boice. The CEO is Charlene Son Rigby. Rare-X was acquired by Global Genes on February 07, 2023. | - |
Walter Kowtoniuk | M | - |
Rare-X
Rare-X Packaged SoftwareTechnology Services Part of Global Genes, Rare-X is a patient advocacy organization based in Washington. Rare-X is focused on supporting the acceleration and development of life-altering treatments and future cures for patients impacted by a rare disease. Rare-X is building the largest collaborative patient-driven, open-data access project for rare diseases ly, gathering structured, fit-for-purpose data to share broadly, benefitting from 21st-century governance, consent, and federated data sharing technology. Rare-X's goal is to build the largest collaborative patient-driven, open-data access project for rare diseases ly. The American company was founded in 2019 by Nicole Boice. The CEO is Charlene Son Rigby. Rare-X was acquired by Global Genes on February 07, 2023. | - |
Simon Frost | M | - |
Rare-X
Rare-X Packaged SoftwareTechnology Services Part of Global Genes, Rare-X is a patient advocacy organization based in Washington. Rare-X is focused on supporting the acceleration and development of life-altering treatments and future cures for patients impacted by a rare disease. Rare-X is building the largest collaborative patient-driven, open-data access project for rare diseases ly, gathering structured, fit-for-purpose data to share broadly, benefitting from 21st-century governance, consent, and federated data sharing technology. Rare-X's goal is to build the largest collaborative patient-driven, open-data access project for rare diseases ly. The American company was founded in 2019 by Nicole Boice. The CEO is Charlene Son Rigby. Rare-X was acquired by Global Genes on February 07, 2023. | - |
Jason Colquitt | M | - |
Rare-X
Rare-X Packaged SoftwareTechnology Services Part of Global Genes, Rare-X is a patient advocacy organization based in Washington. Rare-X is focused on supporting the acceleration and development of life-altering treatments and future cures for patients impacted by a rare disease. Rare-X is building the largest collaborative patient-driven, open-data access project for rare diseases ly, gathering structured, fit-for-purpose data to share broadly, benefitting from 21st-century governance, consent, and federated data sharing technology. Rare-X's goal is to build the largest collaborative patient-driven, open-data access project for rare diseases ly. The American company was founded in 2019 by Nicole Boice. The CEO is Charlene Son Rigby. Rare-X was acquired by Global Genes on February 07, 2023. | - |
Morrie Ruffin | M | - |
Rare-X
Rare-X Packaged SoftwareTechnology Services Part of Global Genes, Rare-X is a patient advocacy organization based in Washington. Rare-X is focused on supporting the acceleration and development of life-altering treatments and future cures for patients impacted by a rare disease. Rare-X is building the largest collaborative patient-driven, open-data access project for rare diseases ly, gathering structured, fit-for-purpose data to share broadly, benefitting from 21st-century governance, consent, and federated data sharing technology. Rare-X's goal is to build the largest collaborative patient-driven, open-data access project for rare diseases ly. The American company was founded in 2019 by Nicole Boice. The CEO is Charlene Son Rigby. Rare-X was acquired by Global Genes on February 07, 2023. | - |
Peter Goodhand | M | - |
Rare-X
Rare-X Packaged SoftwareTechnology Services Part of Global Genes, Rare-X is a patient advocacy organization based in Washington. Rare-X is focused on supporting the acceleration and development of life-altering treatments and future cures for patients impacted by a rare disease. Rare-X is building the largest collaborative patient-driven, open-data access project for rare diseases ly, gathering structured, fit-for-purpose data to share broadly, benefitting from 21st-century governance, consent, and federated data sharing technology. Rare-X's goal is to build the largest collaborative patient-driven, open-data access project for rare diseases ly. The American company was founded in 2019 by Nicole Boice. The CEO is Charlene Son Rigby. Rare-X was acquired by Global Genes on February 07, 2023. | - |
David A. Pearce | M | - |
Rare-X
Rare-X Packaged SoftwareTechnology Services Part of Global Genes, Rare-X is a patient advocacy organization based in Washington. Rare-X is focused on supporting the acceleration and development of life-altering treatments and future cures for patients impacted by a rare disease. Rare-X is building the largest collaborative patient-driven, open-data access project for rare diseases ly, gathering structured, fit-for-purpose data to share broadly, benefitting from 21st-century governance, consent, and federated data sharing technology. Rare-X's goal is to build the largest collaborative patient-driven, open-data access project for rare diseases ly. The American company was founded in 2019 by Nicole Boice. The CEO is Charlene Son Rigby. Rare-X was acquired by Global Genes on February 07, 2023. | - |
Beziehungs-Chart
Beziehungen zu mehreren Unternehmen
Ehemalige Beziehungen
Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
---|---|---|---|---|
Leonard Bell | M | 65 | 25 Jahre | |
David Hallal | M | 56 | 10 Jahre | |
Aradhana Sarin | M | 50 | 4 Jahre | |
Stephen P. Squinto | M | 67 | 23 Jahre | |
Kory Wentworth | M | 45 | 9 Jahre | |
Douglas John Barry | M | 54 | - | |
Ludwig Hantson | M | 61 | 4 Jahre | |
Brian Goff | M | 55 | 4 Jahre | |
Michael V. Greco | M | 53 | 11 Jahre | |
John C. King | M | 49 | 9 Jahre | |
Felix Baker | M | 55 | 6 Jahre | |
William Keller | M | 75 | 6 Jahre | |
Mark Day | M | 52 | 2 Jahre | |
Rana Strellis | F | - | 4 Jahre | |
Michael Ira Kenneth Elloian | M | 52 | - | |
Tina Beamon | F | - | 3 Jahre | |
Judith Reinsdorf | F | 60 | 3 Jahre | |
Susan Altschuller | M | 42 | 2 Jahre | |
Anne-Marie Law | F | 56 | 3 Jahre | |
Francois Nader | M | 67 | 4 Jahre | |
Rockford Norby | M | 89 | 18 Jahre | |
Alvin S. Parven | M | 83 | 19 Jahre | |
M. Burns | F | 66 | 4 Jahre | |
Deborah Dunsire | M | 61 | 3 Jahre | |
Ellen Chiniara | F | 65 | 3 Jahre | |
Paul Friedman | M | 81 | 4 Jahre | |
Lisa Trivison Beck | F | 62 | 3 Jahre | |
Thierry Chauche | M | 48 | 1 Jahre | |
Massimiliano Colao | M | 59 | 3 Jahre | |
Randy Teel | M | 45 | 2 Jahre | |
Jacques Suzanne | F | 53 | 2 Jahre | |
Brian Krex | M | 57 | 4 Jahre | |
Vikas Sinha | M | 60 | 11 Jahre | |
James Loerop | M | 60 | 2 Jahre | |
Jens Renstrup | M | 59 | 3 Jahre | |
Matthew DeLawder | M | - | 5 Jahre | |
Richard Riese | M | 61 | 3 Jahre | |
Laura Gault | F | - | 3 Jahre | |
Kenny Chan | M | - | - | |
Julia Wang | F | 53 | 2 Jahre | |
Christopher Benecchi | M | - | 2 Jahre | |
Kristen Stants | F | 51 | 2 Jahre | |
Martine Zimmermann | M | 55 | 7 Jahre | |
Uzair Qadeer | M | - | 2 Jahre | |
Thomas-Christian Mix | M | 57 | 2 Jahre | |
Mohammed Qatanani | M | 50 | 3 Jahre | |
Micah Zajic | M | 43 | 3 Jahre | |
George Llado | M | 58 | - | |
Behrad Derakhshan | M | 44 | 2 Jahre | |
Rebecca Velez Frey | F | - | 5 Jahre | |
Adam Hansard | M | 48 | 1 Jahre | |
Elena Ridloff | F | 44 | 4 Jahre | |
Melissa Manno | F | - | 2 Jahre | |
Jing Marantz | M | 58 | 2 Jahre | |
Dave Anderson | M | 74 | 1 Jahre | |
Paul Clancy | M | 62 | 2 Jahre | |
Camille Bedrosian | M | 71 | 10 Jahre | |
Stephanie Fagan | F | - | 2 Jahre | |
Paresh N. Soni | M | 63 | 2 Jahre | |
Heidi Wagner | F | 59 | 9 Jahre | |
Tanisha Cariño | M | 49 | 2 Jahre | |
Bill Lundberg | M | 60 | 4 Jahre | |
Jeremy Springhorn | M | 61 | 9 Jahre | |
Saqib Islam | M | 54 | 3 Jahre | |
Christopher J. Stevo | M | - | 1 Jahre | |
Julie O'Neill | F | 58 | 3 Jahre | |
Martin MacKay | M | 68 | 4 Jahre | |
Romesh R. Subramanian | M | 58 | 3 Jahre | |
John Orloff | M | 66 | 4 Jahre | |
Edward Miller | M | 59 | 3 Jahre | |
Mittie Doyle | M | 59 | 3 Jahre | |
Radhika Tripuraneni | M | 44 | - | |
Al Boyle | M | - | 6 Jahre | |
Derek Adams | M | 50 | 11 Jahre | |
Joseph Newell | M | 54 | 2 Jahre | |
James Engelhart | M | 60 | 2 Jahre | |
John Tilton | M | 56 | 10 Jahre | |
Dominique Monnet | M | 65 | 1 Jahre | |
Jason Meyenburg | M | 47 | 13 Jahre | |
Albert Paszek | M | - | 3 Jahre |
Statistik
Land | Beziehungen | % des Gesamten |
---|---|---|
Vereinigte Staaten | 100 | 100,00% |
Alter der Beziehungen
Aktive
Vergangene
Herr
Frau
Aufsichtsräte
Führungskräfte
Ursprung der Beziehungen
- Börse
- Insiders
- John V. W. Reynders
- Persönliches Netzwerk